KDR and sarcoma: Our approach reassuringly identified several targets currently in clinical trials for sarcomas, including IGF1R [166], CD163, EPHB4, FGFR1, KDR, NCAM1, SMO, PSEN1, and PSEN2 [167], and NT5E/CD73 [168].